Market revenue in 2023 | USD 5,443.0 million |
Market revenue in 2030 | USD 9,858.6 million |
Growth rate | 8.9% (CAGR from 2023 to 2030) |
Largest segment | Contract manufacturing |
Fastest growing segment | Contract Development |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Contract Development, Contract Manufacturing |
Key market players worldwide | Catalent Inc, Lonza Group Ltd, Recipharm, Siegfried Holding AG, Thermo Fisher Scientific Inc, Labcorp Drug Development, Jabil Inc, Syngene, IQVIA Holdings Inc, Almac Group, Ajinomoto Co Inc, Alcami, Vetter Pharma-Fertigung |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to healthcare contract development and manufacturing organization market will help companies and investors design strategic landscapes.
Contract manufacturing was the largest segment with a revenue share of 82.23% in 2023. Horizon Databook has segmented the Italy healthcare contract development and manufacturing organization market based on contract development, contract manufacturing covering the revenue growth of each sub-segment from 2018 to 2030.
Italy is one of the largest healthcare CDMO markets in Europe. It is expected to exhibit lucrative growth over the forecast period owing to stringent regulatory policies in the country. Various government organizations, such as Directorate General for Medical Devices and Pharmaceutical Service of Ministry of Health, are responsible for regulating the marketing for medical devices in the country.
According to La Gazzetta del Mezzogiorno, the contract manufacturing industry in the country grew by nearly 40% in 2018, mainly due to increase in exports. Furthermore, according to Pharma World, productivity per unit of the pharma sector in the country was nearly 10% higher than the European mean in 2018, highlighting the availability of skilled labor in the country, which is expected to create growth opportunities for CDMOs.
Horizon Databook provides a detailed overview of country-level data and insights on the Italy healthcare contract development and manufacturing organization market , including forecasts for subscribers. This country databook contains high-level insights into Italy healthcare contract development and manufacturing organization market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account